Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-28T12:42:32.796Z Has data issue: false hasContentIssue false
  • English
  • Français

Use of A Clinical Data Registry to Evaluate Medical Technologies: Experience from the International Bone Marrow Transplant Registry

Published online by Cambridge University Press:  10 March 2009

Alfred A. Rimm ,
Judith T. Barr ,
Mary M. Horowitz  and
Mortimer M. Bortin
Alfred A. Rimm
Affiliation:
Medical College of Wisconsin
Judith T. Barr
Affiliation:
Harvard School of Public Health
Mary M. Horowitz
Affiliation:
Medical College of Wisconsin
Mortimer M. Bortin
Affiliation:
Medical College of Wisconsin
Get access Rights & Permissions [Opens in a new window]

Abstract

We reviewed the 18 disease-specific evaluations that used the data base of the International Bone Marrow Transplant Registry to determine the effectiveness of alternative strategies for bone marrow transplant. We identify 17 treatment variables that physicians can control and report the associations between these variables and five clinical endpoints: stable engraftment, graft-versus-host disease, development of interstitial pneumonia, relapse, and disease-free survival. We also suggest policies to promote active participation in establishing and operating a registry.

Type
Special Section: The Contribution Of Medical Registries To Technology Assessment
Information
International Journal of Technology Assessment in Health Care , Volume 7 , Issue 2 , Spring 1991 , pp. 182 - 193
Copyright
Copyright © Cambridge University Press 1991

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Advisory Committee of the ACS/NIH Bone Marrow Transplant Registry. Bone marrow transplantation from histocompatible, allogeneic donors for aplastic anemia. Journal of the American Medical Association, 1976, 236, 1131–35.CrossRefGoogle Scholar
2.Bortin, M. M., & Rimm, A. A.for the Advisory Committee of the International Bone Marrow Transplant Registry. Severe combined immunodeficiency disease: Characterization of the disease and results of transplantation. Journal of the American Medical Association, 1977, 238, 591–600.CrossRefGoogle Scholar
3.Bortin, M. M., & Rimm, A. A.for the Advisory Committee of the International Bone Marrow Transplant Registry. Bone marrow transplantation for acute myeloblastic leukemia. Journal of the American Medical Association, 1978, 240, 1245–52.CrossRefGoogle Scholar
4.Bortin, M. M., Gale, R. P., & Rimm, A. A.Allogeneic bone marrow transplantation for 144 patients with severe aplastic anemia. Journal of the American Medical Association, 1981, 245, 1132–39.CrossRefGoogle ScholarPubMed
5.Bortin, M. M., Kay, H. E. M., Gale, R. P., & Rimm, A. A.Factors associated with interstitial pneumonitis after bone-marrow transplantation for acute leukaemia. Lancet, 1982, ii, 437–39.CrossRefGoogle Scholar
6.Gale, R. P., Kay, H. E. M., Rimm, A. A., & Bortin, M. M.Bone marrow transplantation for acute leukaemia in first remission. Lancet, 1982, ii, 1006–09.CrossRefGoogle Scholar
7.Bortin, M. M., Gale, R. P., Kay, H. E. M., & Rimm, A. A.Bone marrow transplantation for acute myelogenous leukemia: Factors associated with early mortality. Journal of the American Medical Association, 1983, 249, 1166–75.CrossRefGoogle ScholarPubMed
8.Gale, R. P., Kersey, R. P., Bortin, M. M., et al. Bone marrow transplantation for acute lymphoblastic leukaemia. Lancet, 1983, ii, 663–67.Google Scholar
9.Speck, B., Bortin, M. M., Champlin, R., et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet, 1984, i, 665–68.CrossRefGoogle Scholar
10.Weiner, R. S., Bortin, M. M., Gale, R. P., et al. Interstitial pneumonitis after bone marrow transplantation: Assessment of risk factors. Annals of Internal Medicine, 1986,104,168–75.CrossRefGoogle ScholarPubMed
11.Herzig, R. H., Bortin, M. M., Barrett, A. J., et al. Bone marrow transplantation in high-risk acute lymphoblastic leukaemia in first and second remission. Lancet, 1987, i, 786–89.CrossRefGoogle Scholar
12.Gale, R. P., Bortin, M. M., van Bekkum, D. W., et al. Risk factors for acute graft-versus-host disease. British Journal of Haematology, 1987, 67, 397–406.CrossRefGoogle ScholarPubMed
13.Goldman, J. M., Gale, R. P., Horowitz, M. M., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk for relapse associated with T-cell depletion. Annals of Internal Medicine, 1988, 108, 806–14.CrossRefGoogle ScholarPubMed
14.Champlin, R. E., Horowitz, M. M., van Bekkum, D. W., et al. Graft failure following bone marrow transplantation for severe aplastic anemia: Risk factors and treatment results. Blood, 1989, 73, 606–13.CrossRefGoogle ScholarPubMed
15.International Bone Marrow Transplant Registry. Effect of methotrexate on relapse after bone marrow transplantation for acute lymphoblastic leukaemia. Lancet, 1989, i, 535–37.Google Scholar
16.Weiner, R. S., Horowitz, M. M., Gale, R. P., et al. Risk factors for interstitial pneumonia following bone marrow transplantation for severe aplastic anaemia. British Journal of Haematology, 1989, 71, 535–43.CrossRefGoogle ScholarPubMed
17.International Bone Marrow Transplant Registry. Transplant or chemotherapy in acute myelogenous leukaemia? Lancet, 1989, i, 1119–22.Google Scholar
18.Barrett, A. J., Horowitz, M. M., Gale, R. P., et al. Marrow transplantation for acute lymphoblastic leukaemia: Factors affecting relapse and survival. Blood, 1989, 74, 862–71.CrossRefGoogle ScholarPubMed